香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司 ） （股份代碼：02607） 關連交易 擬參與設立標的基金 合夥協議 董事會欣然宣佈，於2024年10月29日，本公司附屬公司上海生物醫藥前沿產業創新 中心擬訂立合夥協議，内容有關參與設立標的基金，據此，上海生物醫藥前沿產業 創新中心（作為有限合夥人）、國孚領航（作為有限合夥人）、奉賢生物科技（作 為有限合夥人）、奉浦實業（作為有限合夥人）、生命信使（作為有限合夥人）、 鄭效東先生（作為有限合夥人）、項金生先生（作為有限合夥人）、九旺投資（作 為有限合夥人）、安永投資（作為有限合夥人）、曹紅光先生（作為有限合夥 人）、上實資本（作為普通合夥人）及GP2（作為普通合夥人）將分別認購人民幣 250百萬元、人民幣100百萬元、人民幣40百萬元、人民幣30百 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內 容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( ) 於中華人民共和國註冊成立的股份有限公司 (股份代碼: 02607) 持續關連交易 續簽採購框架協議 續簽採購框架協議 於 2024 年 10 月 29 日，本公司與永發印務訂立期限自 2025 年 1 月 1 日起至 2025 年 12 月 31 日止為 期一年的採購框架協議，據此，永發印務集團將向本集團繼續提供藥品的印刷包裝材料。 香港上市規則之含義 鑒於上實集團為本公司及上海實業之控股股東，永發印務為上海實業之間接非全資附屬公司，永發 印務屬於本公司於上市規則第 14A.07 條項下之關連人士。因此，根據上市規則第 14A 章，於採購框 架協議項下與永發印務集團擬進行之交易將構成本公司的持續關連交易。 由於採購框架協議項下擬進行之交易的建議年度上限的最高適用百分比率（上市規則第 ...

Financial Performance - For the first nine months of 2024, the company achieved operating revenue of RMB 209.63 billion, a year-on-year increase of 6.14%[6] - The net profit attributable to shareholders for the same period was RMB 4.05 billion, reflecting a year-on-year growth of 6.78%[6] - The total operating revenue for the reporting period was approximately 70.22 billion RMB, an increase of 8.16% compared to the same period last year[12] - The net profit attributable to shareholders of the listed company was approximately 1.11 billion RMB, a decrease of 6.29% year-on-year[12] - The total profit for the first three quarters of 2024 was ¥6.64 billion, up from ¥6.52 billion in 2023, reflecting an increase of 1.9%[27] - Net profit attributable to shareholders of the parent company reached ¥4.05 billion in 2024, compared to ¥3.80 billion in 2023, marking a growth of 6.8%[27] - The company reported a total comprehensive income of ¥4.99 billion for the first three quarters of 2024, compared to ¥4.78 billion in 2023, an increase of 4.4%[29] Revenue Segmentation - The pharmaceutical manufacturing segment reported sales revenue of RMB 18.28 billion, a decline of 12.10% year-on-year, while the pharmaceutical commerce segment saw sales revenue of RMB 191.35 billion, an increase of 8.28%[6] - The sales revenue from the company's CSO contract promotion business reached approximately 6.1 billion RMB, representing a year-on-year increase of 176.3%[11] - The sales from the company's health equipment business amounted to approximately 32.6 billion RMB, showing a year-on-year growth of 11.9%[11] Cash Flow and Assets - The company reported a net cash inflow from operating activities of RMB 2.78 billion, up 20.87% year-on-year[6] - The net cash flow from operating activities was approximately 2.27 billion RMB, reflecting a significant increase of 241.50%[12] - The company's cash and cash equivalents increased to ¥33,822,817,448.38 from ¥30,517,706,443.04, reflecting a growth of approximately 7.6%[22] - Total assets at the end of the reporting period were approximately 223.74 billion RMB, an increase of 5.55% from the end of the previous year[13] - The total current assets amounted to ¥173,787,729,817.04, up from ¥162,433,862,348.46, representing an increase of about 6.9%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 67,642[20] - The top 10 shareholders collectively hold 1,978,000,000 shares, representing approximately 53.4% of the total shares[19] - The top shareholder, Shanghai Pharmaceutical Group, holds 716,516,039 shares, accounting for 19.34% of the total shares[19] Research and Development - As of the report date, the company has 60 new drug candidates in clinical application or subsequent clinical research stages, including 46 innovative drugs[6] - Research and development expenses increased to ¥1.62 billion in 2024 from ¥1.47 billion in 2023, marking an increase of 10.1%[26] - The company is advancing its traditional Chinese medicine strategy, with ongoing clinical research on six major products[9] Strategic Partnerships - The company signed a strategic cooperation agreement with Sartorius Group to focus on biopharmaceutical innovation incubation and transformation[7] - A strategic cooperation agreement was established with Shanghai Jiao Tong University and other institutions to explore cell therapy[8] Cost Management - The company is implementing cost reduction and efficiency enhancement measures in its pharmaceutical manufacturing operations[10] Investment Income - The company reported a significant increase in investment income by 509.78% during the reporting period[17] - Investment income from joint ventures and associates increased significantly to ¥447.83 million in the first three quarters of 2024, compared to ¥89.92 million in the same period of 2023, representing a growth of 396.5%[27] Financial Ratios - The weighted average return on net assets was 1.58%, a decrease of 0.17 percentage points compared to the previous year[12] - Basic and diluted earnings per share were both ¥1.09 in 2024, up from ¥1.03 in 2023, indicating a growth of 5.8%[29]

Revenue and Profit Performance - Revenue for the first three quarters of 2024 reached 209.629 billion yuan, a year-on-year increase of 6.14%[6] - Revenue for the reporting period was RMB 70.22 billion, an increase of 8.16% year-over-year[10] - Net profit attributable to shareholders was 4.054 billion yuan, a year-on-year increase of 6.78%[6] - Net profit attributable to shareholders of the listed company was RMB 1.11 billion, a decrease of 6.29% year-over-year[10] Pharmaceutical Business Performance - Pharmaceutical industry sales revenue was 18.284 billion yuan, a year-on-year decrease of 12.10%[6] - Pharmaceutical commerce sales revenue was 191.345 billion yuan, a year-on-year increase of 8.28%[6] - Pharmaceutical CSO contract promotion business achieved sales revenue of approximately 6.1 billion yuan, a year-on-year increase of 176.3%[9] - The company successfully introduced 13 imported general agency varieties in the first three quarters of 2024[9] Medical Device and Health Business - Medical device and health business sales reached approximately 32.6 billion yuan, a year-on-year increase of 11.9%[9] - Bayer Health Consumer Goods China Innovation Cooperation Center (CCIP) is expected to invest approximately 20 million euros[8] Cash Flow and Financial Activities - Net cash flow from operating activities was 2.783 billion yuan, a year-on-year increase of 20.87%[6] - Operating cash flow for the reporting period was RMB 2.27 billion, a significant increase of 241.50% year-over-year[10] - Investment activities generated a net cash flow of 3,128,618,459.42, compared to a net outflow of -3,031,028,093.67 in the previous period[31] - Cash inflows from investment activities totaled 22,667,228,186.18, while cash outflows were 19,538,609,726.76[31] - Cash inflows from financing activities amounted to 9,708,395,348.82, with cash outflows of 12,308,051,196.37, resulting in a net cash outflow of -2,599,655,847.55[31] - The net increase in cash and cash equivalents was 304,402,326.97, compared to a net decrease of -227,919,375.59 in the previous period[31] - The ending balance of cash and cash equivalents was 8,234,133,720.99, slightly lower than the previous period's 8,368,403,580.05[31] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 223.74 billion, an increase of 5.55% compared to the end of the previous year[10] - Total assets increased to RMB 223.74 billion as of September 30, 2024, up from RMB 211.97 billion at the end of 2023[18] - Current assets totaled RMB 173.79 billion, with cash and cash equivalents at RMB 33.82 billion[18] - Accounts receivable rose to RMB 83.07 billion, up from RMB 72.93 billion at the end of 2023[18] - Inventory increased to RMB 37.58 billion, compared to RMB 36.62 billion at the end of 2023[18] - Total liabilities stood at RMB 122.53 billion, with short-term borrowings at RMB 38.81 billion[19] - Accounts payable increased to RMB 54.93 billion, up from RMB 47.92 billion at the end of 2023[19] Shareholder and Equity Information - The number of ordinary shareholders at the end of the reporting period was 67,642[14] - The top shareholder, Shanghai Pharmaceutical (Group) Co., Ltd., holds 19.341% of the shares[14] - The company had 67,642 shareholders, including 65,940 A-share holders and 1,702 H-share holders[16] - Total issued shares were 3.70 billion, consisting of 2.79 billion A-shares and 919.07 million H-shares[16] - HKSCC NOMINEES LIMITED held 666.74 million H-shares, representing a significant portion of the H-share capital[15] - Shanghai Industrial Holdings Limited and its subsidiaries held 450.91 million H-shares and 222.30 million A-shares[15] Non-Recurring Items and Investment Income - Non-recurring gains and losses amounted to RMB 131.10 million for the reporting period, with government subsidies contributing RMB 198.83 million[11][12] - Investment income surged by 509.78% due to increased income from joint ventures and associates[13] Financial Instruments and Receivables - Derivative financial liabilities increased by 417.36% due to the rise in fair value of forward foreign exchange contracts[13] - Long-term receivables increased by 152.00% due to an increase in receivables from related parties[13]

证券代码：601607 证券简称：上海医药 编号：临 2024-091 药物名称：硫酸阿托品注射液 剂型：注射剂 规格：1ml:0.5mg 注册分类：化学药品 申请人：上海禾丰制药有限公司 原批准文号：国药准字 H31021172 上海医药集团股份有限公司 关于硫酸阿托品注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）控股子公 司上海禾丰制药有限公司（以下简称"上药禾丰"）收到国家药品监督管理局（以下简 称"国家药监局"）颁发的关于硫酸阿托品注射液（以下简称"该药品"）的《药品补 充申请批准通知书》（通知书编号：2024B03849），该药品通过仿制药质量和疗效一致 性评价。 一、该药品的基本情况 审批结论：本品通过仿制药质量和疗效一致性评价 二、该药品的相关信息 硫酸阿托品注射液主要用于各种内脏绞痛，如胃肠绞痛及膀胱刺激症状；全身麻 醉前给药、严重盗汗和流涎症；迷走神经过度兴奋所致的窦房阻滞、房室阻滞等缓慢 型心律失常，继 ...

证券代码：601607 证券简称：上海医药 编号：临2024-090 上海医药集团股份有限公司 关于 2019 年 A 股股票期权激励计划首次授予股票期权第三 个行权期及预留股票期权第二个行权期 2024 年第三季度自主行权结果公告 重要内容提示： 一、本次股权激励计划已履行的相关审批程序 1、2019 年 9 月 30 日，公司召开第七届董事会第五次会议及第七届监事会 第三次会议，审议通过了《关于 2019 年股票期权激励计划（草案）及其摘要的 议案》（以下简称"《股票期权激励计划（草案）》"）、《关于 2019 年股票期权激 励计划实施考核管理办法的议案》（以下简称"《考核管理办法》"）、《关于提请股 东大会授权董事会办理 2019 年股票期权激励计划相关事宜的议案》。公司董事中 1 上海医药集团股份有限公司（以下简称"上海医药"或"公司"）2019 年 A 股股票期权激励计划（"本次股权激励计划"）首次授予股票期权第三个行 权期可行权股票数量为 6,976,800 份，行权期自 2024 年 2 月 14 日起至 2025 年 2 月 13 日止；预留股票期权第二个行权期可行权的股票期权数量 755,7 ...

Financial Performance - The net profit attributable to shareholders for the first half of 2024 is approximately CNY 2.94 billion, with a proposed cash dividend of CNY 0.80 per 10 shares, totaling CNY 296.28 million, which accounts for 10.07% of the net profit[4]. - The company's operating revenue for the first half of the year reached ¥139.41 billion, an increase of 5.14% compared to ¥132.59 billion in the same period last year[23]. - Net profit attributable to shareholders was ¥2.94 billion, reflecting a growth of 12.72% from ¥2.61 billion year-on-year[23]. - The basic earnings per share increased to ¥0.79, up 11.27% from ¥0.71 in the previous year[25]. - The total assets of the company at the end of the reporting period were ¥221.34 billion, representing a 4.42% increase from ¥211.97 billion at the end of the previous year[23]. - The total amount of non-recurring gains and losses was ¥236.75 million, after accounting for tax effects and minority interests[26]. - The company reported a significant increase in long-term receivables, which rose by 161.71% to RMB 596.54 million from RMB 227.94 million year-on-year[61]. - The company’s total assets included RMB 62.10 billion in overseas assets, accounting for 2.81% of total assets[62]. Dividend and Share Capital - The total share capital as of June 30, 2024, is 3,703,523,491 shares, which will be used as the basis for the dividend distribution[4]. - The report does not include any capital reserve fund conversion into share capital for this reporting period[4]. - The company will not conduct a capital reserve transfer to increase share capital during this reporting period[129]. - A cash dividend of 0.80 yuan per 10 shares (including tax) is proposed for shareholders, based on a total share capital of 3,703,523,491 shares as of June 30, 2024[129]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company emphasizes the importance of risk awareness regarding future plans and development strategies[4]. - The company has implemented strict internal control measures to prevent losses from derivative trading, including clear approval processes and risk management protocols[76]. - The report highlights various risks associated with derivative investments, including market risk, credit risk, and operational risk[76]. Corporate Governance - The report confirms that all board members attended the board meeting, ensuring the accuracy and completeness of the financial report[6]. - The company strictly adheres to the corporate governance code as per the Hong Kong listing rules, although it currently does not meet the gender diversity requirement on the board[134]. - The audit committee has reviewed and approved the accounting treatment methods adopted in the 2024 half-year report[138]. - The company is actively seeking suitable candidates to comply with the gender diversity regulations in the board of directors[134]. Research and Development - The company invested RMB 1.404 billion in R&D, a year-on-year increase of 15.26%, accounting for 11.03% of industrial sales[46]. - The company has 64 new drug pipelines, including 50 innovative drugs, with several in critical research and clinical phases[46]. - The company is actively advancing its cell therapy industrial layout and has initiated clinical trials for its first CAR-T product, B019[45]. - The company is actively responding to the "Healthy China 2030" strategy by increasing innovation investments and optimizing its product offerings[29]. Market and Sales Performance - The pharmaceutical industry segment reported revenue of RMB 12.73 billion, a year-on-year decline of 13.37%, while the pharmaceutical commerce segment generated revenue of RMB 126.68 billion, a year-on-year increase of 7.45%[43]. - The sales amount of the CSO contract promotion business surged to approximately CNY 4 billion, representing a year-on-year increase of 172%[51]. - The sales of non-pharmaceutical businesses, including medical devices and health products, reached approximately CNY 21.8 billion, with a year-on-year growth of about 11.12%[51]. - The sales of health food products from Shanghai Shenyin Microecology Technology Co., Ltd. reached CNY 173 million, reflecting a year-on-year increase of 331%[55]. Investment and Financial Activities - Investment income surged by 223.81% to RMB 246.36 million, compared to a loss of RMB 198.99 million in the previous year[57]. - The company reported a total guarantee amount of 2,524,289,236.08 RMB, which accounts for 3.61% of the company's net assets[167]. - The company has a total of 870,850.00 RMB in credit business with a related party, with actual transactions amounting to 209,257.89 RMB[165]. - The company’s total loan amount from a related party was 209,257.89 RMB during the reporting period[165]. Employee and Stock Options - Shanghai Pharmaceuticals employed 49,234 staff as of June 30, 2024, including 1,674 R&D personnel, focusing on enhancing employee performance and compensation linked to company performance[93]. - The company has implemented an employee stock option incentive plan, with various phases of stock options being exercised as per the announcements[130][132]. - The stock options granted to middle management and core personnel accounted for 77.911% of the total options granted[101]. - The total number of stock options granted under the incentive plan is 24.35572 million, accounting for no more than 1% of the total shares issued by the company as of the report date[3]. Environmental Responsibility - In 2024, the company signed environmental protection responsibility agreements with 20 subsidiaries, enhancing accountability for environmental management[140]. - The group issued a notice outlining six key energy management requirements, aiming to eliminate high-energy-consuming products and improve energy efficiency[141]. - A total of 65 energy-saving technical improvement projects are planned for 2024, with 35 projects completed by the end of the reporting period, expected to save RMB 7.09 million[141].

Investment Rating - The report maintains an "Outperform" rating for Shanghai Pharma (2607 HK) with a target price of HKD 13.82, down 5.0% from previous estimates [3][5][17]. Core Insights - Shanghai Pharma's 1H24 results showed revenue of CNY 139.4 billion, a year-on-year increase of 5.1%, with a notable growth in the Contract Sales Organization (CSO) business, which achieved sales of CNY 4.0 billion, up 172% year-on-year [11][12]. - The pharmaceutical manufacturing segment faced challenges, reporting a revenue decline of 13.4% year-on-year, primarily due to price reductions in products from SPH No.1 Biochemical & Pharmaceutical [12][14]. - The company successfully introduced 8 import varieties and added 15 new SPD projects in 1H24, contributing to its growth despite the overall industry pressure [11][12]. Revenue and Profitability - In 1H24, Shanghai Pharma's gross profit margin (GPM) was 11.6%, down 1.3 percentage points year-on-year, while the net profit attributable to shareholders was CNY 2.94 billion, reflecting a 12.7% increase year-on-year [14][13]. - The report projects revenue for 2024, 2025, and 2026 to be CNY 277.8 billion, CNY 299.9 billion, and CNY 323.5 billion respectively, with growth rates of 6.7%, 8.0%, and 7.9% [16][17]. Accounts Receivable - As of 1H24, Shanghai Pharma's accounts receivable totaled CNY 80.9 billion, with a significant portion due within one year, indicating potential cash flow management challenges [15][4]. Valuation Methodology - The valuation is based on a discounted cash flow (DCF) model using a WACC of 6.2% and a perpetual growth rate of 3%, leading to the target price of HKD 13.82 [5][17].

Financial Performance - The net profit attributable to shareholders for the first half of 2024 is CNY 2,941,911,373.69, with a proposed cash dividend of CNY 0.80 per 10 shares, totaling CNY 296,281,879.28, which accounts for 10.07% of the net profit[3]. - The company's operating revenue for the first half of the year reached ¥139.41 billion, an increase of 5.14% compared to ¥132.59 billion in the same period last year[13]. - Net profit attributable to shareholders was ¥2.94 billion, reflecting a growth of 12.72% from ¥2.61 billion year-on-year[13]. - The net profit after deducting non-recurring gains and losses was ¥2.71 billion, up 23.00% from ¥2.20 billion in the previous year[13]. - The basic earnings per share increased to ¥0.79, representing an 11.27% rise from ¥0.71 in the previous year[14]. - The company's cash flow from operating activities showed a significant decline of 68.55%, totaling ¥515.30 million compared to ¥1.64 billion in the same period last year[13]. - The company reported a net profit of RMB 2,705,163,523.17 for the first half of 2024, representing a 23% increase compared to the same period last year[145]. - The total comprehensive income for the first half of 2023 was RMB 811,247,163.75, indicating a significant year-over-year change[154]. Revenue Breakdown - The pharmaceutical industry segment reported revenue of RMB 12.73 billion, a year-on-year decline of 13.37%, while the pharmaceutical commerce segment achieved revenue of RMB 126.68 billion, a year-on-year increase of 7.45%[29]. - The company's traditional Chinese medicine segment achieved industrial revenue of 5.192 billion RMB in the first half of 2024[35]. - Non-pharmaceutical business sales reached about 21.8 billion RMB, growing approximately 11.12% year-on-year[42]. Research and Development - The company has maintained a leading position in R&D investment intensity, ranking among the top tier of domestic pharmaceutical companies in total R&D investment[24]. - R&D investment increased to 1.404 billion RMB, up 15.26% year-on-year, accounting for 11.03% of industrial sales[34]. - The company has 64 new drug pipelines in clinical research, including 50 innovative drugs and 14 improved new drugs[34]. - The company is actively advancing its cell therapy industrialization layout, having established strategic cooperation with several medical institutions for the development of innovative cell therapy products[31]. Corporate Governance and Management - The company has implemented a scientific committee management approach to optimize its R&D management system and enhance R&D capabilities[33]. - The company has implemented a stock option incentive plan, with a total of 25,600,000 stock options granted to 210 incentive targets initially[68]. - The company aims to enhance corporate governance and prevent talent loss through the incentive plan[70]. - The company has experienced changes in its board and senior management, with key personnel resigning due to work adjustments[91]. Financial Position - The total assets of the company were RMB 221.34 billion, consistent with the total liabilities and equity, indicating a balanced financial position[150]. - The company's equity attributable to shareholders reached RMB 69.99 billion as of June 30, 2024, compared to RMB 68.52 billion at the end of 2023, marking an increase of about 2.2%[150]. - The total liabilities of Shanghai Pharmaceuticals amounted to RMB 221.34 billion, an increase from RMB 211.97 billion as of December 31, 2023, representing a growth of approximately 4.3%[150]. - The company's retained earnings were reported at RMB 35.25 billion as of December 31, 2023, compared to RMB 33.82 billion at the end of 2022, reflecting an increase of about 4.2%[150]. Market Position and Recognition - The company ranked 411th in the 2024 Fortune Global 500, marking its fifth consecutive year on the list[18]. - The company was ranked 42nd in the 2024 Global Pharmaceutical Companies Top 50 by Pharm Exec and 3rd in the 2023 China Pharmaceutical Industry Top 100 by the Southern Pharmaceutical Economic Research Institute[19]. - The company is the second-largest pharmaceutical commercial enterprise in China, with a comprehensive supply chain network covering 25 provinces and municipalities[20]. Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 68.55% to CNY 515.30 million, down from CNY 1.64 billion[45]. - The company reported investment income of RMB 602.80 million, a significant increase from a loss of RMB 198.99 million in the same period last year[152]. - The total cash and cash equivalents at the end of the period reached CNY 33,803,202,802.46, an increase from CNY 28,688,336,307.72 at the end of June 2023[153]. Shareholder Information - The total number of ordinary shareholders reached 70,011 by the end of the reporting period[125]. - The top shareholder, Shanghai Leicai (Group) Co., Ltd., holds 716,516,039 shares, representing 19.347% of the total shares[126]. - The total number of shares increased from 3,703,301,054 to 3,703,523,491, with an addition of 222,437 shares during the reporting period[124]. Compliance and Regulations - The company strictly adhered to the Corporate Governance Code as per Hong Kong listing rules, except for the gender diversity requirement on the board[97]. - The audit committee has reviewed and approved the accounting treatment methods adopted in the 2024 semi-annual report[100]. - The company has committed to ensuring that any equity incentive policies align with the execution of compensation measures[106]. Environmental and Social Responsibility - The company completed the signing of environmental protection responsibility agreements for 20 subsidiaries in the first quarter of 2024[101]. - A total of 65 energy-saving technical improvement projects are planned for 2024, with 35 projects completed by the end of the reporting period, expected to save costs of RMB 7.09 million[101]. - The company aims to establish an ISO50001 system and actively promote photovoltaic project construction as part of its energy management strategy[101].

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥139.41 billion, an increase of 5.14% compared to ¥132.59 billion in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2024 was ¥2.94 billion, representing a 12.72% increase from ¥2.61 billion in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2.71 billion, up 23.00% from ¥2.20 billion year-on-year[19]. - Basic earnings per share increased by 11.27% to CNY 0.79 compared to the same period last year[20]. - Diluted earnings per share also rose by 11.27% to CNY 0.79 year-on-year[20]. - The pharmaceutical industrial segment reported revenue of RMB 12.73 billion, a decline of 13.37%, while the pharmaceutical commercial segment generated revenue of RMB 126.68 billion, an increase of 7.45%[36]. - The net profit attributable to shareholders was RMB 2.94 billion, a year-on-year growth of 12.72%, with the industrial business contributing RMB 1.31 billion and the commercial business contributing RMB 1.79 billion[36]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 68.55%, amounting to ¥515.30 million compared to ¥1.64 billion in the same period last year[19]. - The total assets of the company at the end of the reporting period were ¥221.34 billion, reflecting a 4.42% increase from ¥211.97 billion at the end of the previous year[19]. - The net assets attributable to shareholders increased to ¥69.99 billion, a rise of 2.14% from ¥68.52 billion at the end of the previous year[19]. - The company's total assets included 6.21 billion RMB in overseas assets, accounting for 2.81% of total assets[58]. - The company's asset-liability ratio is 62.85%, an increase of 0.74 percentage points compared to the beginning of the period[74]. Research and Development - The company increased R&D investment to RMB 1.40 billion, a year-on-year rise of 15.26%, accounting for 11.03% of industrial sales[41]. - The company has 64 new drug pipelines in clinical research, including 50 innovative drugs, with 3 in Phase II clinical trials in the U.S.[41]. - The CAR-T product B019 has officially started clinical trials, and the company is collaborating with major medical institutions for cell therapy product development[38]. - The company maintains a strong R&D investment intensity, ranking among the top tier of domestic pharmaceutical companies[31]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of ¥0.80 per 10 shares, totaling ¥296.28 million, which accounts for 10.07% of the net profit for the first half of 2024[6]. - The proposed profit distribution plan includes a cash dividend of RMB 0.8 per 10 shares[117]. - A cash dividend of 0.80 CNY per 10 shares (including tax) is proposed, totaling 296,281,879.28 CNY, based on a total share capital of 3,703,523,491 shares as of June 30, 2024[118]. Environmental Compliance - Shanghai Pharmaceutical Group reported a COD discharge concentration of 92.49 mg/L and a total discharge of 14.03 tons, with a regulatory limit of 49.12 tons[129]. - The company achieved a non-methane hydrocarbon emission of 8.31 tons, with a total hydrocarbon emission of 15.71 tons, demonstrating adherence to air quality regulations[132]. - The company has implemented new strategies to expand its market presence, focusing on sustainable practices and compliance with environmental regulations[132]. - The company is committed to maintaining compliance with national and local environmental standards, ensuring sustainable operations moving forward[132]. Employee Management and Training - As of June 30, 2024, Shanghai Pharmaceuticals employed 49,234 people, including 1,674 in R&D[79]. - During the reporting period, a total of 4,323 employees participated in 15 training sessions, enhancing their professional knowledge and leadership skills[80]. - The company has established a differentiated compensation system for various roles, linking employee income growth to company performance[79]. - The training programs included a new cadre training class and various functional training sessions, reflecting the company's commitment to talent development[80]. Related Party Transactions - The total amount of related party transactions for the company reached CNY 38,442.76 million, accounting for 100% of similar transactions[171]. - The company reported a related party procurement amount of CNY 29,690.67 million, also representing 100% of similar transactions[171]. - The company has a significant reliance on related party transactions, with all reported transactions being at market prices[171]. Corporate Governance - The company strictly adhered to the corporate governance code as per Hong Kong listing rules, except for the gender diversity requirement on the board[122]. - The audit committee has reviewed and approved the accounting treatment methods adopted in the 2024 half-year report[126]. - The company has committed to ensuring the implementation of profit distribution policies to safeguard investor returns[165]. Future Plans and Strategies - The company plans to maintain the distribution amount per share unchanged, adjusting the total distribution amount based on any changes in total share capital before the implementation date[119]. - The company intends to continue investment mergers and acquisitions, overseas business expansion, and digital transformation initiatives[112]. - The company plans to enhance operational efficiency and quality, focusing on R&D innovation and product planning in the industrial sector[112].